Bay Colony Advisory Group Inc d b a Bay Colony Advisors Trims Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Bay Colony Advisory Group Inc d b a Bay Colony Advisors decreased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.5% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,583 shares of the biopharmaceutical company’s stock after selling 93 shares during the period. Bay Colony Advisory Group Inc d b a Bay Colony Advisors’ holdings in Regeneron Pharmaceuticals were worth $831,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. PGGM Investments grew its position in shares of Regeneron Pharmaceuticals by 159.7% during the 2nd quarter. PGGM Investments now owns 84,397 shares of the biopharmaceutical company’s stock worth $44,308,000 after buying an additional 51,900 shares in the last quarter. Founders Capital Management LLC grew its position in shares of Regeneron Pharmaceuticals by 7.0% during the 2nd quarter. Founders Capital Management LLC now owns 8,274 shares of the biopharmaceutical company’s stock worth $4,344,000 after buying an additional 538 shares in the last quarter. Sepio Capital LP grew its position in shares of Regeneron Pharmaceuticals by 33.1% during the 1st quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company’s stock worth $2,150,000 after buying an additional 842 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of Regeneron Pharmaceuticals by 3.9% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company’s stock worth $16,255,000 after buying an additional 955 shares in the last quarter. Finally, Generate Investment Management Ltd bought a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth $6,300,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 0.3%

Regeneron Pharmaceuticals stock opened at $651.80 on Friday. The stock has a market capitalization of $69.08 billion, a PE ratio of 15.61, a price-to-earnings-growth ratio of 2.03 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $883.15. The business has a 50 day simple moving average of $581.80 and a 200-day simple moving average of $565.22. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.72.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. The business had revenue of $3.75 billion during the quarter, compared to analysts’ expectations of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The business’s revenue was up .9% compared to the same quarter last year. During the same period in the previous year, the business earned $12.46 earnings per share. On average, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, December 5th. Stockholders of record on Thursday, November 20th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Thursday, November 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is currently 8.43%.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on REGN. Royal Bank Of Canada increased their price target on Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the stock a “sector perform” rating in a research report on Wednesday. Guggenheim raised their price objective on Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the company a “buy” rating in a research report on Wednesday. Sanford C. Bernstein raised their price target on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an “outperform” rating in a report on Wednesday, August 27th. Wells Fargo & Company raised their price target on Regeneron Pharmaceuticals from $580.00 to $615.00 and gave the stock an “equal weight” rating in a report on Wednesday. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 8th. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $802.36.

Insider Activity

In other news, Director Christine A. Poon sold 6,500 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total value of $4,252,755.00. Following the sale, the director directly owned 2,352 shares of the company’s stock, valued at $1,538,843.04. The trade was a 73.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 7.02% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.